Pub Date : 2025-02-15eCollection Date: 2025-01-01DOI: 10.62347/QIEZ3054
Hasan Dinc, Sükrü Oguz, Selcuk Akkaya, Elif Merve Bal, Atilla Türkyılmaz, Bekir Sami Karapolat, Celal Tekinbaş
Chylothorax development following blunt abdominal trauma is a rare event. While low volume chylothoraxes usually improve with conservative treatment, invasive interventions are required in high-volume chylothoraxes with daily drainage exceeding 1000 ml. We report a case of a 14-year-old boy who developed high-volume (>3 L/d) chylothorax on the left side following blunt abdominal trauma. The patient did not respond to conservative treatments. He underwent thoracic duct ligation three times, with percutaneous lymphatic interventions, and percutaneous Lipiodol-glue mixture injections under computed tomography (CT) guidance, but all treatments were unsuccessful. We describe the four-month multidisciplinary challenge in this case that was ultimately successfully treated by surgical ligation of aberrant and/or collateral lymphatics draining from the left abdomen to the left pleural cavity, with the help of the novel cone-beam computed tomography (CBCT) lymphangiography (LAG) technique.
{"title":"Overcoming therapeutic challenges in a case of refractory chylothorax following blunt abdominal trauma through the utility of cone-beam computed tomography lymphangiography.","authors":"Hasan Dinc, Sükrü Oguz, Selcuk Akkaya, Elif Merve Bal, Atilla Türkyılmaz, Bekir Sami Karapolat, Celal Tekinbaş","doi":"10.62347/QIEZ3054","DOIUrl":"10.62347/QIEZ3054","url":null,"abstract":"<p><p>Chylothorax development following blunt abdominal trauma is a rare event. While low volume chylothoraxes usually improve with conservative treatment, invasive interventions are required in high-volume chylothoraxes with daily drainage exceeding 1000 ml. We report a case of a 14-year-old boy who developed high-volume (>3 L/d) chylothorax on the left side following blunt abdominal trauma. The patient did not respond to conservative treatments. He underwent thoracic duct ligation three times, with percutaneous lymphatic interventions, and percutaneous Lipiodol-glue mixture injections under computed tomography (CT) guidance, but all treatments were unsuccessful. We describe the four-month multidisciplinary challenge in this case that was ultimately successfully treated by surgical ligation of aberrant and/or collateral lymphatics draining from the left abdomen to the left pleural cavity, with the help of the novel cone-beam computed tomography (CBCT) lymphangiography (LAG) technique.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"15 1","pages":"48-55"},"PeriodicalIF":1.3,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: Percutaneous coronary intervention (PCI) is a critical procedure for improving blood flow by alleviating arterial blockage. However, its availability in Ethiopia is limited because of insufficient resources, staff, and infrastructure.
Objective: To evaluate the clinical characteristics and outcomes of patients who underwent percutaneous coronary intervention at Gesund Cardiac and Medical Center in Addis Ababa, Ethiopia, in 2024.
Methods: This retrospective observational chart review included 224 patients who underwent percutaneous coronary intervention. Data were collected using a standardized checklist, imported into EPI information v7, and analyzed using SPSS v26. A binary logistic regression model was used to identify factors associated with percutaneous coronary intervention.
Results: The study found that most participants (n = 186, 83%) were male, with a mean age of 57.82 ± 11.5 years. Diabetes mellitus was prevalent among participants (n = 135, 60.3%), followed by hypertension (n = 127, 56.7%). A notable portion (n = 31, 13.8%) had previously undergone percutaneous coronary intervention. Most patients presented with typical chest pain, with ST-Elevation Myocardial Infarction (STEMI) being the primary indication for percutaneous coronary intervention. Post-procedure complications includes significant bleeding (n = 6, 2.6%), myocardial infarction (n = 20, 8.9%), death (n = 2, 0.9%), transfer to another hospital (n = 12, 5.4%), and acute kidney injury (n = 16, 7.14%). The use of bare metal stents was significantly associated with transfer to other hospitals (AOR = 5; 95% CI = 1.69-10.29). Male gender (AOR = 0.09; 95% CI = 0.03-0.34) and a history of myocardial infarction (AOR = 10; 95% CI = 2.31-13.31) were linked to an increased risk of post-percutaneous coronary intervention death.
Conclusion and recommendations: Our findings suggest that coronary artery stenosis (CAS) is more prevalent in older individuals and men. Chronic illnesses often coexist with coronary artery stenosis, thereby complicating the prognosis. Interestingly, men exhibited a lower risk of unfavorable outcomes compared to women. Adherence to procedural guidelines and effective management techniques are essential for improving patient outcomes following percutaneous coronary intervention.
{"title":"Clinical characteristics and outcomes of patients undergoing percutaneous coronary intervention at Gesund Cardiac and Medical Center, Addis Ababa, Ethiopia, 2024.","authors":"Kesete Eskias, Alemayehu Bekele, Ousman Adal, Heyria Hussien, Lemlem Beza Demisse","doi":"10.62347/RIAQ1956","DOIUrl":"10.62347/RIAQ1956","url":null,"abstract":"<p><strong>Introduction: </strong>Percutaneous coronary intervention (PCI) is a critical procedure for improving blood flow by alleviating arterial blockage. However, its availability in Ethiopia is limited because of insufficient resources, staff, and infrastructure.</p><p><strong>Objective: </strong>To evaluate the clinical characteristics and outcomes of patients who underwent percutaneous coronary intervention at Gesund Cardiac and Medical Center in Addis Ababa, Ethiopia, in 2024.</p><p><strong>Methods: </strong>This retrospective observational chart review included 224 patients who underwent percutaneous coronary intervention. Data were collected using a standardized checklist, imported into EPI information v7, and analyzed using SPSS v26. A binary logistic regression model was used to identify factors associated with percutaneous coronary intervention.</p><p><strong>Results: </strong>The study found that most participants (n = 186, 83%) were male, with a mean age of 57.82 ± 11.5 years. Diabetes mellitus was prevalent among participants (n = 135, 60.3%), followed by hypertension (n = 127, 56.7%). A notable portion (n = 31, 13.8%) had previously undergone percutaneous coronary intervention. Most patients presented with typical chest pain, with ST-Elevation Myocardial Infarction (STEMI) being the primary indication for percutaneous coronary intervention. Post-procedure complications includes significant bleeding (n = 6, 2.6%), myocardial infarction (n = 20, 8.9%), death (n = 2, 0.9%), transfer to another hospital (n = 12, 5.4%), and acute kidney injury (n = 16, 7.14%). The use of bare metal stents was significantly associated with transfer to other hospitals (AOR = 5; 95% CI = 1.69-10.29). Male gender (AOR = 0.09; 95% CI = 0.03-0.34) and a history of myocardial infarction (AOR = 10; 95% CI = 2.31-13.31) were linked to an increased risk of post-percutaneous coronary intervention death.</p><p><strong>Conclusion and recommendations: </strong>Our findings suggest that coronary artery stenosis (CAS) is more prevalent in older individuals and men. Chronic illnesses often coexist with coronary artery stenosis, thereby complicating the prognosis. Interestingly, men exhibited a lower risk of unfavorable outcomes compared to women. Adherence to procedural guidelines and effective management techniques are essential for improving patient outcomes following percutaneous coronary intervention.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"15 1","pages":"29-38"},"PeriodicalIF":1.3,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11928886/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: Postoperative pulmonary complications (POPC) are common after cardiac surgeries such as coronary artery bypass grafting (CABG) and are influenced by factors including anesthesia and surgical trauma. Inspiratory muscle training (IMT) with visual biofeedback may mitigate these complications. This study investigates the impact of threshold loading inspiratory muscle training (TL-IMT) combined with respiratory biofeedback on the dynamic strength of inspiratory muscles (S-index) in patients undergoing CABG surgery during their hospitalization phase.
Methods: A single-blind study was conducted with 38 CABG candidates at Shahid Modares Hospital, Tehran. Participants were randomized into two groups: the TL-IMT with biofeedback group and the placebo IMT group. TL-IMT exercises were performed at 30% of maximum dynamic inspiratory strength using the Power Breath K5 device, with visual biofeedback displayed on the screen. The placebo group performed the same exercises at minimal load without biofeedback. Both groups received standard respiratory physiotherapy. Measurements of S-index, peak inspiratory flow (PIF), and vital capacity (VC) were taken before surgery (T1), one day after surgery (T2), and at discharge (T3).
Results: Both groups showed significant changes, with a decrease from T1 to T2 and an increase from T2 to T3. In the study group, T3 values remained the same as at T1, while the placebo IMT group experienced a significant decrease. After surgery, both groups had a drop in the S-index. However, the study group saw more pronounced changes between T3-T2 and T3-T1 compared to the control group, although no significant difference was found between T2-T1. By the time of discharge, the TL-IMT group had higher S-index values than the placebo group, returning to preoperative levels. Additionally, the TL-IMT group showed improvements in PIF and VC.
Conclusion: TL-IMT with visual biofeedback effectively maintains dynamic inspiratory muscle strength and improves key pulmonary parameters in cardiac surgery patients. These findings suggest that integrating TL-IMT with biofeedback can enhance postoperative recovery and reduce the incidence of POPC.
{"title":"The impact of threshold-loaded inspiratory muscle training and respiratory biofeedback on preserving inspiratory muscle strength and vital capacity after CABG: a randomized clinical trial.","authors":"Bahareh Mehregan-Far, Sedigheh Sadat Naimi, Mohsen Abedi, Parsa Salemi, Seyed Ahmad Raeis-Sadat, Mahmood Beheshti-Monfared","doi":"10.62347/JBMU4830","DOIUrl":"10.62347/JBMU4830","url":null,"abstract":"<p><strong>Objectives: </strong>Postoperative pulmonary complications (POPC) are common after cardiac surgeries such as coronary artery bypass grafting (CABG) and are influenced by factors including anesthesia and surgical trauma. Inspiratory muscle training (IMT) with visual biofeedback may mitigate these complications. This study investigates the impact of threshold loading inspiratory muscle training (TL-IMT) combined with respiratory biofeedback on the dynamic strength of inspiratory muscles (S-index) in patients undergoing CABG surgery during their hospitalization phase.</p><p><strong>Methods: </strong>A single-blind study was conducted with 38 CABG candidates at Shahid Modares Hospital, Tehran. Participants were randomized into two groups: the TL-IMT with biofeedback group and the placebo IMT group. TL-IMT exercises were performed at 30% of maximum dynamic inspiratory strength using the Power Breath K5 device, with visual biofeedback displayed on the screen. The placebo group performed the same exercises at minimal load without biofeedback. Both groups received standard respiratory physiotherapy. Measurements of S-index, peak inspiratory flow (PIF), and vital capacity (VC) were taken before surgery (T1), one day after surgery (T2), and at discharge (T3).</p><p><strong>Results: </strong>Both groups showed significant changes, with a decrease from T1 to T2 and an increase from T2 to T3. In the study group, T3 values remained the same as at T1, while the placebo IMT group experienced a significant decrease. After surgery, both groups had a drop in the S-index. However, the study group saw more pronounced changes between T3-T2 and T3-T1 compared to the control group, although no significant difference was found between T2-T1. By the time of discharge, the TL-IMT group had higher S-index values than the placebo group, returning to preoperative levels. Additionally, the TL-IMT group showed improvements in PIF and VC.</p><p><strong>Conclusion: </strong>TL-IMT with visual biofeedback effectively maintains dynamic inspiratory muscle strength and improves key pulmonary parameters in cardiac surgery patients. These findings suggest that integrating TL-IMT with biofeedback can enhance postoperative recovery and reduce the incidence of POPC.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"375-383"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/CXMD7229
Mohammad Reza Movahed
Patients presenting with severe acute cardiogenic pulmonary edema with hypoxia commonly require intubation until heart failure treatments take effect. A new term describing similar condition is called sympathetic crashing acute pulmonary edema (SCAPE). It is also called Flash pulmonary edema. Immediate pre- and afterload reduction can abort intubation. Using rapid repeated buccal administrations of nitroglycerin ointments can prevent intubation by rapidly reducing pre- and afterload as long as systolic blood pressure remains adequate without cardiogenic shock. A case series of 6 patients who needed intubation due to severe cardiogenic pulmonary edema and hypoxia despite 100% O2 administration without the presence of cardiogenic shock were successfully treated with repeated buccal administration of nitroglycerin ointments. Approximately half of an inch of nitroglycerin ointment (nitropaste) was buccally administrated every 60 seconds as long as repeated blood pressure measurements every minute before each repeated administration remained above 120 mmHg. Complete response with resolution of dyspnea with minimal oxygen requirement achieved in less than 30 minutes in all patients. Intubation was prevented in all 6 patients. No adverse events occurred in any of the patients. A treatment protocol and algorithm are developed based on these patients and reported cases in the literature for prevention of intubation in these patients. Rapid repeated buccal administration of nitroglycerin ointment is highly effective in preventing intubation and mechanical ventilation in patients with any acute pulmonary edema or SCAPE and hypoxia without cardiogenic shock.
{"title":"The Movahed protocol and algorithm for preventing intubation in patients with acute or sympathetic crashing acute pulmonary edema (SCAPE) without cardiogenic shock by repeated administration of buccal nitroglycerin ointments.","authors":"Mohammad Reza Movahed","doi":"10.62347/CXMD7229","DOIUrl":"10.62347/CXMD7229","url":null,"abstract":"<p><p>Patients presenting with severe acute cardiogenic pulmonary edema with hypoxia commonly require intubation until heart failure treatments take effect. A new term describing similar condition is called sympathetic crashing acute pulmonary edema (SCAPE). It is also called Flash pulmonary edema. Immediate pre- and afterload reduction can abort intubation. Using rapid repeated buccal administrations of nitroglycerin ointments can prevent intubation by rapidly reducing pre- and afterload as long as systolic blood pressure remains adequate without cardiogenic shock. A case series of 6 patients who needed intubation due to severe cardiogenic pulmonary edema and hypoxia despite 100% O2 administration without the presence of cardiogenic shock were successfully treated with repeated buccal administration of nitroglycerin ointments. Approximately half of an inch of nitroglycerin ointment (nitropaste) was buccally administrated every 60 seconds as long as repeated blood pressure measurements every minute before each repeated administration remained above 120 mmHg. Complete response with resolution of dyspnea with minimal oxygen requirement achieved in less than 30 minutes in all patients. Intubation was prevented in all 6 patients. No adverse events occurred in any of the patients. A treatment protocol and algorithm are developed based on these patients and reported cases in the literature for prevention of intubation in these patients. Rapid repeated buccal administration of nitroglycerin ointment is highly effective in preventing intubation and mechanical ventilation in patients with any acute pulmonary edema or SCAPE and hypoxia without cardiogenic shock.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"368-374"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/AXZC9187
Kiana Seifouri, Reza Kahdemi, Fatemeh Ahmadi Hajikolaei, Fatemeh Rasekh, Fariba Azadikhah, Ida Mehraban, Reyhaneh Alikhani, Alireza Mirjalili, Milad Alipour, Sayedeh-Fatemeh Sadat-Madani, Fatemeh Chichagi, Saeed Zivari Lashkajani, Amir Abdi, Mohaddeseh Belbasi, Ata Akhtari Kohnehshahri, Niloofar Deravi, Mahdyieh Naziri, Yasamin Pishkari, Melika Arab Bafrani, Vahid Aghsaghloo, Ali Faghih Habibi
Background and aims: Depression is a prevalent comorbidity among patients with coronary heart disease (CHD). While recent studies have hinted at a possible association between CHD and antidepressant medications like sertraline, the existing evidence remains inconclusive. To investigate this potential link, we conducted a comprehensive systematic review.
Methods: We systematically searched PubMed, Google Scholar, and Scopus for relevant articles published up to March 2023. After a thorough screening of titles and abstracts, 12 studies were included in our review.
Results: The included studies, spanning from 1999 to 2021, comprised 11 randomized controlled trials (RCTs) and one pilot study. A total of 2767 participants with major depressive disorder and a history of cardiovascular disease or at risk for such events were included. The majority of these studies demonstrated improvements in mood status among patients treated with serotonin-targeting antidepressants and a reduced risk of cardiovascular events, as measured by various outcomes. While some cardiac adverse effects were observed with serotonin treatment, these did not reach statistical significance.
Conclusion: Our findings provide evidence supporting the beneficial effects of serotonin-targeting antidepressants for both depressive symptoms and the prevention of coronary adverse outcomes. These results highlight the potential value of serotonin-based treatments for depression in high-risk populations.
{"title":"Sertraline in depressed patients with or at risk for coronary heart disese: a systemic review.","authors":"Kiana Seifouri, Reza Kahdemi, Fatemeh Ahmadi Hajikolaei, Fatemeh Rasekh, Fariba Azadikhah, Ida Mehraban, Reyhaneh Alikhani, Alireza Mirjalili, Milad Alipour, Sayedeh-Fatemeh Sadat-Madani, Fatemeh Chichagi, Saeed Zivari Lashkajani, Amir Abdi, Mohaddeseh Belbasi, Ata Akhtari Kohnehshahri, Niloofar Deravi, Mahdyieh Naziri, Yasamin Pishkari, Melika Arab Bafrani, Vahid Aghsaghloo, Ali Faghih Habibi","doi":"10.62347/AXZC9187","DOIUrl":"10.62347/AXZC9187","url":null,"abstract":"<p><strong>Background and aims: </strong>Depression is a prevalent comorbidity among patients with coronary heart disease (CHD). While recent studies have hinted at a possible association between CHD and antidepressant medications like sertraline, the existing evidence remains inconclusive. To investigate this potential link, we conducted a comprehensive systematic review.</p><p><strong>Methods: </strong>We systematically searched PubMed, Google Scholar, and Scopus for relevant articles published up to March 2023. After a thorough screening of titles and abstracts, 12 studies were included in our review.</p><p><strong>Results: </strong>The included studies, spanning from 1999 to 2021, comprised 11 randomized controlled trials (RCTs) and one pilot study. A total of 2767 participants with major depressive disorder and a history of cardiovascular disease or at risk for such events were included. The majority of these studies demonstrated improvements in mood status among patients treated with serotonin-targeting antidepressants and a reduced risk of cardiovascular events, as measured by various outcomes. While some cardiac adverse effects were observed with serotonin treatment, these did not reach statistical significance.</p><p><strong>Conclusion: </strong>Our findings provide evidence supporting the beneficial effects of serotonin-targeting antidepressants for both depressive symptoms and the prevention of coronary adverse outcomes. These results highlight the potential value of serotonin-based treatments for depression in high-risk populations.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"318-329"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/JOYM3506
Fatemeh Chichagi, Kimiya Ghanbari-Mardasi, Niyousha Shirsalimi, Mahboobeh Sheikh, Diaa Hakim
Objectives: This systematic review aimed to review existing evidence to evaluate the effects of physical cardiac rehabilitation on cardio-pulmonary outcomes in the patients with hypertrophic cardiomyopathy (HCM).
Methods: We conducted a systematic search of the databases PubMed, Web of Science, Embase, Scopus, and Google Scholar. The initial search led to 1222 citations after removing duplicate results. We included only English-written studies published since 2013 (2013-2023). Ultimately, we retrieved five studies, involving 235 participants. We used the Cochrane Risk of Bias Tool for randomized trials (RoB2) and risk of bias in non-randomized studies of intervention (ROBINS-I) for evaluating the risk of bias in randomized and non-randomized studies, respectively.
Results: Results showed that four training programs improved participants' functional capacity by up to 46%. Improvements in weight, BMI, echocardiography, and remodeling parameters (left atrium volume index, premature ventricular contraction burden, pulmonary artery systolic pressure), exercise test results (minute ventilation/carbon dioxide production, peak workload, heart rate reserve, exercise duration, peak heart rate, peak systolic pressure, and blood pressure response to exercise normalization), and a decrease in N- Terminal Pro-Brain Natriuretic Peptide (NT-pro BNP) were reported in these studies. No major adverse events, including sustained tachyarrhythmia, implantable cardioverter-defibrillator discharge, and sudden cardiac death were reported.
Conclusion: Supervised exercise training is safe and helpful for patients diagnosed with HCM. It can improve exercise capacity and is considered an adjunctive therapeutic option.
目的:本系统综述旨在回顾现有证据,以评估心脏物理康复对肥厚性心肌病(HCM)患者心肺预后的影响。方法:系统检索PubMed、Web of Science、Embase、Scopus、谷歌Scholar等数据库。在删除重复结果后,最初的搜索导致1222次引用。我们只纳入了2013年(2013-2023年)以来发表的英语写作研究。最终,我们检索了5项研究,涉及235名参与者。我们分别使用Cochrane随机试验偏倚风险工具(RoB2)和非随机干预研究偏倚风险工具(ROBINS-I)来评估随机和非随机研究的偏倚风险。结果:结果表明,四种训练方案提高了参与者的功能能力高达46%。改善体重、BMI、超声心动图和重塑参数(左心房容积指数、室性早搏负荷、肺动脉收缩压)、运动试验结果(分钟通气量/二氧化碳生成、峰值负荷、心率储备、运动持续时间、心率峰值、收缩压峰值和血压对运动正常化的反应);这些研究报道了N端原脑钠肽(NT-pro BNP)的减少。无重大不良事件,包括持续的心动过速、植入式心律转复除颤器放电和心源性猝死。结论:有监督的运动训练对HCM患者是安全有益的。它可以提高运动能力,被认为是一种辅助治疗选择。
{"title":"Physical cardiac rehabilitation effects on cardio-metabolic outcomes in the patients with hypertrophic cardiomyopathy: a systematic review.","authors":"Fatemeh Chichagi, Kimiya Ghanbari-Mardasi, Niyousha Shirsalimi, Mahboobeh Sheikh, Diaa Hakim","doi":"10.62347/JOYM3506","DOIUrl":"10.62347/JOYM3506","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review aimed to review existing evidence to evaluate the effects of physical cardiac rehabilitation on cardio-pulmonary outcomes in the patients with hypertrophic cardiomyopathy (HCM).</p><p><strong>Methods: </strong>We conducted a systematic search of the databases PubMed, Web of Science, Embase, Scopus, and Google Scholar. The initial search led to 1222 citations after removing duplicate results. We included only English-written studies published since 2013 (2013-2023). Ultimately, we retrieved five studies, involving 235 participants. We used the Cochrane Risk of Bias Tool for randomized trials (RoB2) and risk of bias in non-randomized studies of intervention (ROBINS-I) for evaluating the risk of bias in randomized and non-randomized studies, respectively.</p><p><strong>Results: </strong>Results showed that four training programs improved participants' functional capacity by up to 46%. Improvements in weight, BMI, echocardiography, and remodeling parameters (left atrium volume index, premature ventricular contraction burden, pulmonary artery systolic pressure), exercise test results (minute ventilation/carbon dioxide production, peak workload, heart rate reserve, exercise duration, peak heart rate, peak systolic pressure, and blood pressure response to exercise normalization), and a decrease in N- Terminal Pro-Brain Natriuretic Peptide (NT-pro BNP) were reported in these studies. No major adverse events, including sustained tachyarrhythmia, implantable cardioverter-defibrillator discharge, and sudden cardiac death were reported.</p><p><strong>Conclusion: </strong>Supervised exercise training is safe and helpful for patients diagnosed with HCM. It can improve exercise capacity and is considered an adjunctive therapeutic option.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"330-341"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/AAPZ2726
Seyed Mohammad Mahdi Meybodi, Mohammad Amin Karimi, Kourosh Mousazadeh, Kamyar Khorsand, Samira Masoumi, Seyed Abbas Pakmehr, Mahsa Asadi Anar, Nahid Samadi, Mohadeseh Poudineh, Mohammad Rahmanian, Shirin Yaghoobpoor, Arash Rahimi, Fariba Arbab Mojeni, Seyedeh Zahra Banihashemian, Mina Masoodi, Komeil Aghazadeh-Habashi, Atousa Ghorbani, Arezoo Faridzadeh, Niloofar Deravi
Background and aim: Sodium-glucose cotransporter two inhibitors can reduce cardiovascular events by modulating lipid profiles in patients with heart failure, irrespective of diabetes status. In this study, we aimed to assess the effects of SGLT-2 inhibitors on the lipid profiles of patients with heart failure via a meta-analysis.
Methods: The PubMed, Scopus, Web of Science, and Google Scholar databases were searched up to 2023 to retrieve relevant article titles, abstracts, and full texts. STATA software was used to conduct the meta-analysis.
Result: The Forest plot of fasting blood sugar levels in patients receiving SGLT-2 inhibitors differed significantly from those the in control group (mean difference = -0.08, 95% CI [-0.13, -0.02], P < 0.05). Analysis of lipid profile parameters, including total cholesterol, triglyceride, HDL, and LDL in patients with HF receiving SGLT-2 inhibitors, did not show a notable difference from the control group (P > 0.005). However, the mean difference was towards the reduction of LDL, cholesterol, and triglycerides and showed an increase in HDL levels. Egger's test for publication bias revealed some publication bias (P < 0.05).
Conclusion: Our topic analysis did not reveal any notable alterations in the lipid profile. To arrive at a more definite agreement, further research on subjects with heart failure is necessary because there is currently insufficient evidence.
背景和目的:钠-葡萄糖共转运蛋白2抑制剂可以通过调节心力衰竭患者的脂质谱来减少心血管事件,而与糖尿病状态无关。在这项研究中,我们旨在通过荟萃分析评估SGLT-2抑制剂对心力衰竭患者脂质谱的影响。方法:检索截至2023年的PubMed、Scopus、Web of Science和谷歌Scholar数据库,检索相关文章标题、摘要和全文。采用STATA软件进行meta分析。结果:SGLT-2抑制剂组空腹血糖Forest图与对照组有显著差异(平均差异= -0.08,95% CI [-0.13, -0.02], P < 0.05)。接受SGLT-2抑制剂的HF患者的血脂参数分析,包括总胆固醇、甘油三酯、HDL和LDL,与对照组没有显着差异(P < 0.05)。然而,平均差异是低密度脂蛋白、胆固醇和甘油三酯的降低,高密度脂蛋白水平升高。Egger's发表偏倚检验显示有一定的发表偏倚(P < 0.05)。结论:我们的主题分析没有发现任何显著的血脂变化。为了达成更明确的共识,有必要对心力衰竭患者进行进一步的研究,因为目前证据不足。
{"title":"The influence of SGLT-2 inhibitors on lipid profiles in heart failure patients: a systematic review and meta-analysis.","authors":"Seyed Mohammad Mahdi Meybodi, Mohammad Amin Karimi, Kourosh Mousazadeh, Kamyar Khorsand, Samira Masoumi, Seyed Abbas Pakmehr, Mahsa Asadi Anar, Nahid Samadi, Mohadeseh Poudineh, Mohammad Rahmanian, Shirin Yaghoobpoor, Arash Rahimi, Fariba Arbab Mojeni, Seyedeh Zahra Banihashemian, Mina Masoodi, Komeil Aghazadeh-Habashi, Atousa Ghorbani, Arezoo Faridzadeh, Niloofar Deravi","doi":"10.62347/AAPZ2726","DOIUrl":"10.62347/AAPZ2726","url":null,"abstract":"<p><strong>Background and aim: </strong>Sodium-glucose cotransporter two inhibitors can reduce cardiovascular events by modulating lipid profiles in patients with heart failure, irrespective of diabetes status. In this study, we aimed to assess the effects of SGLT-2 inhibitors on the lipid profiles of patients with heart failure via a meta-analysis.</p><p><strong>Methods: </strong>The PubMed, Scopus, Web of Science, and Google Scholar databases were searched up to 2023 to retrieve relevant article titles, abstracts, and full texts. STATA software was used to conduct the meta-analysis.</p><p><strong>Result: </strong>The Forest plot of fasting blood sugar levels in patients receiving SGLT-2 inhibitors differed significantly from those the in control group (mean difference = -0.08, 95% CI [-0.13, -0.02], P < 0.05). Analysis of lipid profile parameters, including total cholesterol, triglyceride, HDL, and LDL in patients with HF receiving SGLT-2 inhibitors, did not show a notable difference from the control group (P > 0.005). However, the mean difference was towards the reduction of LDL, cholesterol, and triglycerides and showed an increase in HDL levels. Egger's test for publication bias revealed some publication bias (P < 0.05).</p><p><strong>Conclusion: </strong>Our topic analysis did not reveal any notable alterations in the lipid profile. To arrive at a more definite agreement, further research on subjects with heart failure is necessary because there is currently insufficient evidence.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"295-305"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/EWMH1925
Fatemeh Chichagi, Reyhaneh Alikhani, Mohammad Hossein Hosseini, Kiarash Azadi, Niyousha Shirsalimi, Saeed Ghodsi, Mana Jameie
Objectives: To our knowledge, there is no clear consensus on a definitive cardiac rehabilitation method for patients undergoing Coronary Artery Bypass Graft (CABG). We conducted this systematic review to compare and evaluate the effects of two of the most frequent cardiac rehabilitation modalities, high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT), on cardiopulmonary variables.
Methods: We carried out a systematic search of the databases PubMed, Web of Science, Embase, Scopus, and Google Scholar. Following the removal of duplicate results, the original search yielded 385 citations. We identified four randomized clinical trials after reviewing titles, abstracts, and potential full-text studies. We utilized the Cochrane Risk of Bias Tool (RoB2) to assess the risk of bias.
Results: We included four randomized clinical trials involving 143 people. All trials included individuals who had CABG and completed HIIT or MICT sessions for at least four weeks. The findings indicated that HIIT programs may improve functional capacity, heart rate variability indices, and blood pressure management while lowering brain natriuretic peptide (BNP1-32) and N-terminal pro-b-type natriuretic peptide (NT-proBNP1-76) levels.
Conclusion: Given the findings, it appeared that supervised high-intensity exercise regimens could be more useful to patients. Following the surgery, HIIT therapy improves exercise capacity, the autonomic nervous system, volume overload, and blood pressure regulation.
目的:据我们所知,对于冠状动脉旁路移植术(CABG)患者的心脏康复方法尚无明确的共识。我们进行了这一系统综述,以比较和评估两种最常见的心脏康复方式,高强度间歇训练(HIIT)和中等强度连续训练(MICT)对心肺变量的影响。方法:系统检索PubMed、Web of Science、Embase、Scopus、谷歌Scholar等数据库。在删除重复结果之后,原始搜索产生了385次引用。在回顾了题目、摘要和潜在的全文研究后,我们确定了四项随机临床试验。我们使用Cochrane风险偏倚工具(RoB2)来评估偏倚风险。结果:我们纳入了四项随机临床试验,涉及143人。所有的试验都包括CABG和完成HIIT或MICT至少四周的个体。研究结果表明,HIIT方案可以改善功能能力、心率变异性指标和血压管理,同时降低脑钠肽(BNP1-32)和n端前b型钠肽(NT-proBNP1-76)水平。结论:鉴于这些发现,似乎有监督的高强度运动方案对患者更有用。手术后,HIIT治疗可改善运动能力、自主神经系统、容量过载和血压调节。
{"title":"The effects of high-intensity interval training and moderate-intensity continuous training on patients underwent Coronary Artery Bypass Graft surgery; a systematic review.","authors":"Fatemeh Chichagi, Reyhaneh Alikhani, Mohammad Hossein Hosseini, Kiarash Azadi, Niyousha Shirsalimi, Saeed Ghodsi, Mana Jameie","doi":"10.62347/EWMH1925","DOIUrl":"10.62347/EWMH1925","url":null,"abstract":"<p><strong>Objectives: </strong>To our knowledge, there is no clear consensus on a definitive cardiac rehabilitation method for patients undergoing Coronary Artery Bypass Graft (CABG). We conducted this systematic review to compare and evaluate the effects of two of the most frequent cardiac rehabilitation modalities, high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT), on cardiopulmonary variables.</p><p><strong>Methods: </strong>We carried out a systematic search of the databases PubMed, Web of Science, Embase, Scopus, and Google Scholar. Following the removal of duplicate results, the original search yielded 385 citations. We identified four randomized clinical trials after reviewing titles, abstracts, and potential full-text studies. We utilized the Cochrane Risk of Bias Tool (RoB2) to assess the risk of bias.</p><p><strong>Results: </strong>We included four randomized clinical trials involving 143 people. All trials included individuals who had CABG and completed HIIT or MICT sessions for at least four weeks. The findings indicated that HIIT programs may improve functional capacity, heart rate variability indices, and blood pressure management while lowering brain natriuretic peptide (BNP<sub>1-32</sub>) and N-terminal pro-b-type natriuretic peptide (NT-proBNP<sub>1-76</sub>) levels.</p><p><strong>Conclusion: </strong>Given the findings, it appeared that supervised high-intensity exercise regimens could be more useful to patients. Following the surgery, HIIT therapy improves exercise capacity, the autonomic nervous system, volume overload, and blood pressure regulation.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"306-317"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/HYCA6457
Nismat Javed, Vikram Itare, Sai Vishnu Vardhan Allu, Shalini Penikilapate, Neelanjana Pandey, Nisha Ali, Preeti Jadhav, Sridhar Chilimuri, Jonathan N Bella
Objectives: Cardiogenic shock is a significant economic burden on healthcare facilities and patients. The prevalence and outcome of cardiogenic shock in the South Bronx are unknown. The aim of the study was to examine the burden of non-AMI CS in Hispanic and Black population in South Bronx and characterize their in-hospital outcomes.
Methods: We reviewed patient charts between 1/1/2022 and 1/1/2023 to identify patients with a primary diagnosis of cardiogenic shock (ICD codes R57.0, R57, R57.8, R57.9) residing in the following zip codes: 10451-59 and 10463. Student's T-test was used to assess differences for continuous variables; chi-square statistic was used for categorical variables. A logistic regression analysis model was used to assess independent predictors of mortality. A P-value of < 0.05 was considered significant.
Results: 87 patients were admitted with cardiogenic shock (60% African American, 67% male, mean age =62±15 years) of which 54 patients (62%) died. Those who died were older, had > 1 pressor, out-of-hospital arrest, arrested within 24 hours of admission, and had higher SCAI class, lactate, and ALT levels than those who were discharged. The logistic regression analysis model showed that older age ((RR=3.4 [95% CI: 3.3-3.45]), > 1 pressor (RR=3.4 [95% CI: 2.6-4.2]) and higher SCAI class (2.1 [95% CI: 1.5-2.1], all P < 0.05)) were independent predictors of mortality in patients with cardiogenic shock. Additionally, most of the patients had either Medicare or Medicaid insurance in predominantly African American study population.
Conclusions: Cardiogenic shock carries a significant risk of death. Factors such as advanced age, the administration of more than one vasopressor, and a higher SCAI classification have been identified as independent predictors of mortality among inpatients with cardiogenic shock. Additionally, the progression and outcomes of the condition are influenced by variables like race (e.g., African American individuals in this study) and economic challenges, including the type of insurance coverage (e.g., Medicaid or Medicare). Further research is essential to explore strategies that could enhance survival rates in cardiogenic shock patients, with a particular focus on addressing economic and racial disparities.
{"title":"Burden and predictors of mortality related to cardiogenic shock in the South Bronx Population.","authors":"Nismat Javed, Vikram Itare, Sai Vishnu Vardhan Allu, Shalini Penikilapate, Neelanjana Pandey, Nisha Ali, Preeti Jadhav, Sridhar Chilimuri, Jonathan N Bella","doi":"10.62347/HYCA6457","DOIUrl":"10.62347/HYCA6457","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiogenic shock is a significant economic burden on healthcare facilities and patients. The prevalence and outcome of cardiogenic shock in the South Bronx are unknown. The aim of the study was to examine the burden of non-AMI CS in Hispanic and Black population in South Bronx and characterize their in-hospital outcomes.</p><p><strong>Methods: </strong>We reviewed patient charts between 1/1/2022 and 1/1/2023 to identify patients with a primary diagnosis of cardiogenic shock (ICD codes R57.0, R57, R57.8, R57.9) residing in the following zip codes: 10451-59 and 10463. Student's T-test was used to assess differences for continuous variables; chi-square statistic was used for categorical variables. A logistic regression analysis model was used to assess independent predictors of mortality. A <i>P</i>-value of < 0.05 was considered significant.</p><p><strong>Results: </strong>87 patients were admitted with cardiogenic shock (60% African American, 67% male, mean age =62±15 years) of which 54 patients (62%) died. Those who died were older, had > 1 pressor, out-of-hospital arrest, arrested within 24 hours of admission, and had higher SCAI class, lactate, and ALT levels than those who were discharged. The logistic regression analysis model showed that older age ((RR=3.4 [95% CI: 3.3-3.45]), > 1 pressor (RR=3.4 [95% CI: 2.6-4.2]) and higher SCAI class (2.1 [95% CI: 1.5-2.1], all P < 0.05)) were independent predictors of mortality in patients with cardiogenic shock. Additionally, most of the patients had either Medicare or Medicaid insurance in predominantly African American study population.</p><p><strong>Conclusions: </strong>Cardiogenic shock carries a significant risk of death. Factors such as advanced age, the administration of more than one vasopressor, and a higher SCAI classification have been identified as independent predictors of mortality among inpatients with cardiogenic shock. Additionally, the progression and outcomes of the condition are influenced by variables like race (e.g., African American individuals in this study) and economic challenges, including the type of insurance coverage (e.g., Medicaid or Medicare). Further research is essential to explore strategies that could enhance survival rates in cardiogenic shock patients, with a particular focus on addressing economic and racial disparities.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"355-367"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744217/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-12-15eCollection Date: 2024-01-01DOI: 10.62347/TSPL4520
Leighton A Hope, Timothy Chrusciel, Bilal Abuhaiba, Div Verma, Ravi Nayak, Mina M Benjamin
Background: We compared long-term clinical outcomes between patients with cardiac sarcoidosis (CS) who received no treatment (NT), steroid treatment (ST), disease-modifying anti-rheumatic drugs (DMARDs), or tumor necrosis factor alpha inhibitors (TNF).
Methods: Patients from SSM healthcare system's data warehouse were identified using ICD codes. Inclusion criteria included at least 6 months of follow-up. Outcomes studied were heart failure (HF) admissions, ventricular tachyarrhythmias (VTA), and pacemaker/defibrillator placement. Statistical analysis included multivariate logistic regression and Kaplan-Meier curves.
Results: We identified 198, 174, 66, and 19 patients in NT, ST, DMARDs, and TNF groups respectively. Mean age was 62.4, 60.2, 56, and 54.4 respectively. There was no significant difference in the rate of medical comorbidities including pulmonary sarcoidosis between the groups. Mean follow up was 92.3 months. Percent incidences of VTA were 17.5, 16.3, 12.5, and 5.6 (P 0.57) in the NT, ST, DMARDs and TNF groups respectively. DMARDs and TNF groups had a lower incidence of HF admission (43.9% and 36.8%) compared to NT and ST (59.1% and 59.2%). In the multivariate model, compared to NT group, the odds ratio for HF admission was 1.08 (CI: 0.70-1.65), 0.64 (0.36-1.14) and 0.45 (0.17-1.20) in the ST, DMARDs and TNF groups respectively. There was no significant difference in the rate of pacemaker/defibrillator placement between the groups.
Conclusion: In this retrospective study from a large healthcare system, CS patients treated with DMARDs or TNF had a trend for lower incidence of HF admission than those on NT or ST.
{"title":"Comparison of long-term outcomes in patients with cardiac sarcoidosis treated with different immunosuppressive drugs.","authors":"Leighton A Hope, Timothy Chrusciel, Bilal Abuhaiba, Div Verma, Ravi Nayak, Mina M Benjamin","doi":"10.62347/TSPL4520","DOIUrl":"10.62347/TSPL4520","url":null,"abstract":"<p><strong>Background: </strong>We compared long-term clinical outcomes between patients with cardiac sarcoidosis (CS) who received no treatment (NT), steroid treatment (ST), disease-modifying anti-rheumatic drugs (DMARDs), or tumor necrosis factor alpha inhibitors (TNF).</p><p><strong>Methods: </strong>Patients from SSM healthcare system's data warehouse were identified using ICD codes. Inclusion criteria included at least 6 months of follow-up. Outcomes studied were heart failure (HF) admissions, ventricular tachyarrhythmias (VTA), and pacemaker/defibrillator placement. Statistical analysis included multivariate logistic regression and Kaplan-Meier curves.</p><p><strong>Results: </strong>We identified 198, 174, 66, and 19 patients in NT, ST, DMARDs, and TNF groups respectively. Mean age was 62.4, 60.2, 56, and 54.4 respectively. There was no significant difference in the rate of medical comorbidities including pulmonary sarcoidosis between the groups. Mean follow up was 92.3 months. Percent incidences of VTA were 17.5, 16.3, 12.5, and 5.6 (P 0.57) in the NT, ST, DMARDs and TNF groups respectively. DMARDs and TNF groups had a lower incidence of HF admission (43.9% and 36.8%) compared to NT and ST (59.1% and 59.2%). In the multivariate model, compared to NT group, the odds ratio for HF admission was 1.08 (CI: 0.70-1.65), 0.64 (0.36-1.14) and 0.45 (0.17-1.20) in the ST, DMARDs and TNF groups respectively. There was no significant difference in the rate of pacemaker/defibrillator placement between the groups.</p><p><strong>Conclusion: </strong>In this retrospective study from a large healthcare system, CS patients treated with DMARDs or TNF had a trend for lower incidence of HF admission than those on NT or ST.</p>","PeriodicalId":7427,"journal":{"name":"American journal of cardiovascular disease","volume":"14 6","pages":"342-354"},"PeriodicalIF":1.3,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11744215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142998619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}